Select a medication above to begin.
androstenolone
DHEA
Reported Doses
Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely
Special Note
- [formulation clarification]
- Info: may include DHEA, DHEA-S metabolite; see prasterone vaginal for FDA-approved Rx product; all other preparations are not FDA-approved
Effectiveness Ratings
- [see Herb & Supplement Effectiveness Rating Definitions table]
Addison disease
- [Insufficient Evidence]
- Dose: 50 mg PO qd
adrenal insufficiency
- [Insufficient Evidence]
- Dose: 20-50 mg PO qd
androgen deficiency, partial
- [Insufficient Evidence]
- Dose: 25 mg PO qd
cervical dysplasia
- [Insufficient Evidence]
- Dose: 150 mg PV qd
chronic fatigue syndrome
- [Insufficient Evidence]
- Dose: 25-100 mg PO qd
COPD
- [Insufficient Evidence]
- Dose: 200 mg PO qd
Crohn disease
- [Insufficient Evidence]
- Dose: 200 mg PO qd
depression
- [Possibly Effective]
- Dose: 30-500 mg PO qd
erectile dysfunction
- [Insufficient Evidence]
- Dose: 50 mg PO qd
exercise-induced muscle damage
- [Insufficient Evidence]
- Dose: 50 mg PO bid
HIV/AIDS
- [Insufficient Evidence]
- Dose: 50-500 mg PO qd
menopausal symptoms
- [Insufficient Evidence]
- Dose: 10-25 mg PO qd; Alt: 3.5-13 mg PV qd
metabolic syndrome
- [Insufficient Evidence]
- Dose: 50-100 mg PO qd
muscular dystrophy
- [Insufficient Evidence]
- Dose: 200 mg IV qd
osteoporosis
- [Insufficient Evidence]
- Dose: 50-100 mg PO qd
parturition
- [Insufficient Evidence]
- Dose: 50-200 mg IV 1-2x/wk; Alt: 100 mg IV qd x3 days; Start: after 37 wk gestation
schizophrenia
- [Insufficient Evidence]
- Dose: 50 mg PO bid; Start: 25 mg PO qd x2wk, then 25 mg PO bid x2wk, then 50 mg PO bid
sexual dysfunction
- [Insufficient Evidence]
- Dose: 300 mg PO x1; Alt 50-500 mg PO qd; 0.25-1% cream or suppository PV qd
skin aging
- [Possibly Effective]
- Dose: 50 mg PO qd; Alt: apply 1% cream topically qd
SLE
- [Insufficient Evidence]
- Dose: 20-200 mg PO qd
ulcerative colitis
- [Insufficient Evidence]
- Dose: 200 mg PO qd
vaginal atrophy
- [Likely Effective]
- Dose: 0.25-1% suppository PV qd; Alt; apply 10% cream to inner thighs qd
Copyright © 2026. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.